Preterm lambs given intravenous dopamine show increased dopamine in their cerebrospinal fluid

Elisabeth Olhager, Claudia Annelie Nold, Mandar Joshi, James C G Doery, Thilini Damsarani Samarasinghe, Adrian Mark Walker, Flora Yuen-Wait Wong

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Dopamine is used as an inotropic medication in preterm infants. The preterm human blood brain barrier (BBB) is permeable to intravascular dopamine, and the impact of exogenous dopamine on the preterm brain remains unknown. The preterm lamb model may be suitable for studying the cerebral impact of dopamine therapy whether its BBB permeability is similar to preterm human infants. We aimed to examine BBB permeability to exogenous dopamine in the preterm lamb, by measuring dopamine levels in the cerebrospinal fluid (CSF). METHODS: Nine preterm foetal lambs (125-130 days, term = 147 days) were given either dopamine at 10 mug/kg/min (dopamine, n = 4) or saline (control, n = 5). CSF, and plasma samples were taken for dopamine assay. RESULTS: The median (range) baseline CSF dopamine level for the combined control and dopamine groups (n = 9) was 0.10(0.03-0.16) ng/mL, and baseline plasma dopamine was 0.30(0.13-0.84) ng/mL. The dopamine lambs showed increase in CSF dopamine to 3.91(1.87-11.35) ng/mL with plasma dopamine increased to 14.2 (9.1-57.9) ng/mL. No change was found in the control lambs. CONCLUSION: In the preterm lamb, the BBB permeability and pharmacokinetics to dopamine infusion are similar to findings in the preterm human infant, supporting applicability of the preterm lamb model for studying effects of dopamine infusion in the preterm human brain.
Original languageEnglish
Pages (from-to)337 - 342
Number of pages6
JournalActa Paediatrica
Volume103
Issue number3
DOIs
Publication statusPublished - 2014

Cite this

@article{3ab8b9f2b2084bcb98d0becd03e9a1a2,
title = "Preterm lambs given intravenous dopamine show increased dopamine in their cerebrospinal fluid",
abstract = "Dopamine is used as an inotropic medication in preterm infants. The preterm human blood brain barrier (BBB) is permeable to intravascular dopamine, and the impact of exogenous dopamine on the preterm brain remains unknown. The preterm lamb model may be suitable for studying the cerebral impact of dopamine therapy whether its BBB permeability is similar to preterm human infants. We aimed to examine BBB permeability to exogenous dopamine in the preterm lamb, by measuring dopamine levels in the cerebrospinal fluid (CSF). METHODS: Nine preterm foetal lambs (125-130 days, term = 147 days) were given either dopamine at 10 mug/kg/min (dopamine, n = 4) or saline (control, n = 5). CSF, and plasma samples were taken for dopamine assay. RESULTS: The median (range) baseline CSF dopamine level for the combined control and dopamine groups (n = 9) was 0.10(0.03-0.16) ng/mL, and baseline plasma dopamine was 0.30(0.13-0.84) ng/mL. The dopamine lambs showed increase in CSF dopamine to 3.91(1.87-11.35) ng/mL with plasma dopamine increased to 14.2 (9.1-57.9) ng/mL. No change was found in the control lambs. CONCLUSION: In the preterm lamb, the BBB permeability and pharmacokinetics to dopamine infusion are similar to findings in the preterm human infant, supporting applicability of the preterm lamb model for studying effects of dopamine infusion in the preterm human brain.",
author = "Elisabeth Olhager and Nold, {Claudia Annelie} and Mandar Joshi and Doery, {James C G} and Samarasinghe, {Thilini Damsarani} and Walker, {Adrian Mark} and Wong, {Flora Yuen-Wait}",
year = "2014",
doi = "10.1111/apa.12520",
language = "English",
volume = "103",
pages = "337 -- 342",
journal = "Acta Paediatrica",
issn = "0803-5253",
publisher = "Wiley-Blackwell",
number = "3",

}

Preterm lambs given intravenous dopamine show increased dopamine in their cerebrospinal fluid. / Olhager, Elisabeth; Nold, Claudia Annelie; Joshi, Mandar; Doery, James C G; Samarasinghe, Thilini Damsarani; Walker, Adrian Mark; Wong, Flora Yuen-Wait.

In: Acta Paediatrica, Vol. 103, No. 3, 2014, p. 337 - 342.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Preterm lambs given intravenous dopamine show increased dopamine in their cerebrospinal fluid

AU - Olhager, Elisabeth

AU - Nold, Claudia Annelie

AU - Joshi, Mandar

AU - Doery, James C G

AU - Samarasinghe, Thilini Damsarani

AU - Walker, Adrian Mark

AU - Wong, Flora Yuen-Wait

PY - 2014

Y1 - 2014

N2 - Dopamine is used as an inotropic medication in preterm infants. The preterm human blood brain barrier (BBB) is permeable to intravascular dopamine, and the impact of exogenous dopamine on the preterm brain remains unknown. The preterm lamb model may be suitable for studying the cerebral impact of dopamine therapy whether its BBB permeability is similar to preterm human infants. We aimed to examine BBB permeability to exogenous dopamine in the preterm lamb, by measuring dopamine levels in the cerebrospinal fluid (CSF). METHODS: Nine preterm foetal lambs (125-130 days, term = 147 days) were given either dopamine at 10 mug/kg/min (dopamine, n = 4) or saline (control, n = 5). CSF, and plasma samples were taken for dopamine assay. RESULTS: The median (range) baseline CSF dopamine level for the combined control and dopamine groups (n = 9) was 0.10(0.03-0.16) ng/mL, and baseline plasma dopamine was 0.30(0.13-0.84) ng/mL. The dopamine lambs showed increase in CSF dopamine to 3.91(1.87-11.35) ng/mL with plasma dopamine increased to 14.2 (9.1-57.9) ng/mL. No change was found in the control lambs. CONCLUSION: In the preterm lamb, the BBB permeability and pharmacokinetics to dopamine infusion are similar to findings in the preterm human infant, supporting applicability of the preterm lamb model for studying effects of dopamine infusion in the preterm human brain.

AB - Dopamine is used as an inotropic medication in preterm infants. The preterm human blood brain barrier (BBB) is permeable to intravascular dopamine, and the impact of exogenous dopamine on the preterm brain remains unknown. The preterm lamb model may be suitable for studying the cerebral impact of dopamine therapy whether its BBB permeability is similar to preterm human infants. We aimed to examine BBB permeability to exogenous dopamine in the preterm lamb, by measuring dopamine levels in the cerebrospinal fluid (CSF). METHODS: Nine preterm foetal lambs (125-130 days, term = 147 days) were given either dopamine at 10 mug/kg/min (dopamine, n = 4) or saline (control, n = 5). CSF, and plasma samples were taken for dopamine assay. RESULTS: The median (range) baseline CSF dopamine level for the combined control and dopamine groups (n = 9) was 0.10(0.03-0.16) ng/mL, and baseline plasma dopamine was 0.30(0.13-0.84) ng/mL. The dopamine lambs showed increase in CSF dopamine to 3.91(1.87-11.35) ng/mL with plasma dopamine increased to 14.2 (9.1-57.9) ng/mL. No change was found in the control lambs. CONCLUSION: In the preterm lamb, the BBB permeability and pharmacokinetics to dopamine infusion are similar to findings in the preterm human infant, supporting applicability of the preterm lamb model for studying effects of dopamine infusion in the preterm human brain.

UR - http://onlinelibrary.wiley.com/doi/10.1111/apa.12520/epdf

U2 - 10.1111/apa.12520

DO - 10.1111/apa.12520

M3 - Article

VL - 103

SP - 337

EP - 342

JO - Acta Paediatrica

JF - Acta Paediatrica

SN - 0803-5253

IS - 3

ER -